Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a, Proof of Concept, Multicenter, Double Blind, Randomized, Placebo Controlled, Parallel Group Trial to Assess the Efficacy and Safety of ACT-777991 in Adults With Non-segmental Vitiligo

Next Previous
Trial Profile

A Phase 2a, Proof of Concept, Multicenter, Double Blind, Randomized, Placebo Controlled, Parallel Group Trial to Assess the Efficacy and Safety of ACT-777991 in Adults With Non-segmental Vitiligo

Status: Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Sep 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ACT-777991 (Primary)
  • Indications Vitiligo
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Idorsia Pharmaceuticals

Most Recent Events

  • 31 Jul 2026 According to Idorsia media release, initiation activities are ongoing across US and European sites.
  • 25 Jun 2026 Status changed from planning to not yet recruiting.
  • 30 Oct 2025 According to Idorsia media release, the trial is expected to begin in 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top